MA-ECHOSENS
Echosens , a high-technology company offering the FibroScan® family of products, announces the release of new guidelines from the European Association for the Study of the Liver (EASL), a professional association for individuals researching liver disease. These guidelines represent a significant advance for the non-invasive management of patients with liver diseases and an unprecedented level of recommendation for Echosens’ solutions.
“We’re very pleased that these new guidelines are very prescriptive for FibroScan parameters, positioning our technologies as the cornerstone of non-invasive tests (NIT) for the future of liver disease management—across the liver care continuum and all population groups,” says Dominique Legros, Group CEO, Echosens. “As the NIT of reference, FibroScan combines standardization, clinical performance and accessibility for early patient identification, in first-line after Fib-4, either in primary care, diabetology clinic or liver clinic, and for advanced liver disease patient management, portal hypertension and hepatocellular carcinoma (HCC) risk stratification.”
EASL guidelines highlights include:
- Liver stiffness measurement (LSM ) by transient elastography (TE ) received support from 13 “strong recommendations” and four other recommendations or supportive statements.
- Controlled attenuation parameter (CAP) is now mentioned in the guidelines, with clear cut-off for steatosis diagnosis.
- Spleen stiffness measurement (SSM) is now recommended as an additional NIT to further improve risk stratification and refine the risk of high-risk varices.
Across all population groups, FibroScan was mentioned in 18 recommendations or statements, including in non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), hepatitis C virus, including post sustained virologic response (PSVR), primary biliary cirrhosis (PBC)/primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH), as well as in at-risk populations, such as patients with metabolic risk factors and/or harmful use of alcohol. All recommended cut-off values are clearly specified for LSM by TE.
Jon Gingrich, CEO, Echosens North America, says, “We’re highly gratified by these new guidelines, which further demonstrate the value of FibroScan for comprehensive management of liver health in the battle against a global liver disease epidemic. EASL is a key facilitator of excellence in liver research and liver-related innovation.”
About Echosens
Pioneer in its field, Echosens significantly changed the practice of liver assessment with FibroScan® , the non-invasive solution for comprehensive management of liver health. FibroScan® is recognized worldwide and validated by over 2,500 peer reviewed publications and 70 international guidelines. Echosens has made FibroScan® available in over 100+ countries enabling millions of liver examinations worldwide. https://www.echosens.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005125/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KCAS Bio Strengthens Board of Directors with Appointment of Paul Kirchgraber and Kurt Doyle3.11.2025 09:30:00 CET | Press release
KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites in the greater Philadelphia area; Lyon, France; and a partnership in Melbourne, Australia. The Company is backed by Vitruvian Partners, one of the world’s leading growth-focused investment firms. Dr. Paul Kirchgraber brings decades of leadership experience in clinical research and laboratory operations. He served as Executive Vice President and CEO of Covance, Labcorp’s Drug Development Division, where he led global teams in drug and medical device development in over 60 countries. Dr. Kirchgraber has experience running global p
Eric Jing: Ant Group to Strengthen Support for Hong Kong's Global Finance and Tech Leadership with AI, GoGlobal Services3.11.2025 09:19:00 CET | Press release
Eric Jing, Chairman of Ant Group, reaffirmed Ant’s commitment to deepening cross-sector collaboration on regulated AI and tokenization innovation in the territory, and to expanding its cross-border payment and trade financing services to support Hong Kong’s initiative to help Chinese businesses go global. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251102787084/en/ John Lee, Chief Executive of Hong Kong SAR visited the booths of Ant International and Ant Digital Technologies during the 10th annual Hong Kong Fintech Week on November 3, 2025. Speaking on a panel with Christopher Hui, Hong Kong’s Secretary for Financial Services and the Treasury, and Fred Hu, Founder, Chairman and CEO of Primavera Capital Group at the 10th annual Hong Kong Fintech Week on November 3, 2025, Jing said the City’s visionary and prudent approach to policy innovation, rich commercial and financial use cases and a robust ecosystem of cross-sector c
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region3.11.2025 09:00:00 CET | Press release
Julie Dehaene-Puype joins Kyowa Kirin as new President of the International RegionJeremy Morgan will retire at the end of December 2025 after a two-month leadership transition period Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceutical Company, today announced the appointment of Julie Dehaene-Puype as President for the Region, effective 1 November 2025. Julie follows the tenure of Jeremy Morgan, who has served as President for the International Region since 2023. Morgan will serve in an advisor role to the business through to the end of 2025, working in partnership with Dehaene-Puype to ensure a successful and smooth change for the company. “We are very pleased to welcome Julie to the company in the role as President of KKI,” said Tomohiro Sudo, Chief International Business Officer of Kyowa Kirin. “Julie joins us with extensive experience in global biotech and pharma spanning a 25-year caree
SPM International Launches SPM Academy Inc. – a New Global Center for ISO-Compliant Vibration Training and Certification3.11.2025 09:00:00 CET | Press release
SPM Instrument, a global leader in condition monitoring, is taking the next step in its mission to empower industries with knowledge and tools that ensure reliability and performance. SPM Academy Inc., based in the U.S., will serve as a worldwide hub for vibration training and certification, strengthening industrial reliability expertise across sectors. Led by Bill Partipilo, CEO of SPM Instrument North America, the Academy builds on SPM’s long tradition of innovation and customer support through learning. “Our new global training center gives maintenance and reliability professionals the chance to develop their skills through interactive, high-quality course materials – in their local language, on a platform or location that suits them,” said Partipilo. SPM Academy combines practical exercises, simulators, and real-world case studies for a dynamic learning experience. Training and certification follow ISO/IEC 17024, ISO 18436-1, and ISO 18436-2. The SPM Academy Certification Center is
Merz Aesthetics® Introduces New BELOTERO®Syringe Offering Greater Precision, Comfort and Ease of Use3.11.2025 08:00:00 CET | Press release
Redesigned syringe seamlessly blends innovation and functionality, setting a new standard for precision and ease in the injection experience. Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO®*.The new syringe is ergonomically engineered to elevate the treatment experience, offering greater precision, comfort, and ease of use. The new syringe will launch first in Europe, and then will expand to markets worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251102677784/en/ “As the first region to introduce this innovation ahead of our global expansion, I’m proud to share this exciting milestone in BELOTERO®’s history as a trusted leader in hyaluronic acid treatments,” said Gonzalo Mibelli, President EMEA region. What is BELOTERO®? BELOTERO® is a thoughtfully designed, comprehensive range of hi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom